Strs Ohio increased its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) by 9.4% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 29,100 shares of the company’s stock after acquiring an additional 2,500 shares during the period. Strs Ohio’s holdings in Y-mAbs Therapeutics were worth $419,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of YMAB. Lazard Asset Management LLC acquired a new position in Y-mAbs Therapeutics during the second quarter worth approximately $85,000. Amalgamated Bank acquired a new position in Y-mAbs Therapeutics during the first quarter worth approximately $68,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Y-mAbs Therapeutics by 248.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,513 shares of the company’s stock worth $99,000 after buying an additional 4,645 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in Y-mAbs Therapeutics by 172.5% during the second quarter. BNP Paribas Arbitrage SA now owns 7,980 shares of the company’s stock worth $121,000 after buying an additional 5,052 shares during the last quarter. Finally, Principal Financial Group Inc. acquired a new position in Y-mAbs Therapeutics during the second quarter worth approximately $160,000. Institutional investors own 53.96% of the company’s stock.
Y-mAbs Therapeutics Stock Down 3.2 %
YMAB stock opened at $4.54 on Friday. The company has a market cap of $198.25 million, a PE ratio of -1.48 and a beta of 0.74. The business has a 50-day simple moving average of $4.58 and a 200 day simple moving average of $11.17. Y-mAbs Therapeutics, Inc. has a 52 week low of $2.94 and a 52 week high of $20.48.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on YMAB. Cowen downgraded Y-mAbs Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 5th. BMO Capital Markets decreased their target price on Y-mAbs Therapeutics from $29.00 to $12.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 1st. HC Wainwright decreased their target price on Y-mAbs Therapeutics from $63.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday, October 31st. Morgan Stanley decreased their target price on Y-mAbs Therapeutics from $17.00 to $8.00 and set an “equal weight” rating on the stock in a research report on Monday, October 31st. Finally, JPMorgan Chase & Co. downgraded Y-mAbs Therapeutics from a “neutral” rating to an “underweight” rating and reduced their price target for the stock from $16.00 to $7.00 in a research report on Monday, October 31st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $14.33.
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.
- Get a free copy of the StockNews.com research report on Y-mAbs Therapeutics (YMAB)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.